Cargando…

Retrospective analysis of severe COVID-19 pneumonia patients treated with lopinavir/ritonavir: A comparison with survivor and non-survivor patients

BACKGROUND: Currently there is no proven medical treatment for COVID-19. We aimed to determine the factors affecting mortality and changes in clinical and laboratory findings in patients with severe COVID-19 pneumonia treated with lopinavir/ritonavir (Lpv/r). METHODS: Data of survivor and non-surviv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayten, Omer, Saylan, Bengu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AOSIS 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378208/ https://www.ncbi.nlm.nih.gov/pubmed/34485485 http://dx.doi.org/10.4102/sajid.v35i1.233

Ejemplares similares

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
por: Mazan, Paula, et al.
Publicado: (2020)

Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
por: Wada, Tatsuhiko, et al.
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir
por: Mas Serrano, Miguel, et al.
Publicado: (2020)

The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism
por: Caliskan, Tayfun, et al.
Publicado: (2021)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients
por: Gao, Guiju, et al.
Publicado: (2020)

Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b
por: Hong, Sun In, et al.
Publicado: (2020)

Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
por: Zanon, D., et al.
Publicado: (2020)

Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
por: Koba, Hayato, et al.
Publicado: (2020)

Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series
por: Surabotsophon, Manoon, et al.
Publicado: (2020)

Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients
Publicado: (2022)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
por: Lecronier, Marie, et al.
Publicado: (2020)

A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
por: Joumaa, H., et al.
Publicado: (2020)

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
por: Cao, Bin, et al.
Publicado: (2020)

Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study
por: Kim, Jongkyu, et al.
Publicado: (2021)

Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients
por: Baslilar, Seyma, et al.
Publicado: (2021)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
por: Owa, Adewale Bayode, et al.
Publicado: (2020)

Potentially fatal severe brady arrythmias related to Lopinavir-Ritonavir in a COVID 19 patient
por: Shree, Venkatesan, et al.
Publicado: (2021)

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
por: Klement-Frutos, Elise, et al.
Publicado: (2021)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
por: Kaizer, Alexander M., et al.
Publicado: (2023)

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir()
por: Brandariz-Nuñez, David, et al.
Publicado: (2020)

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
por: Ader, Florence
Publicado: (2022)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan
por: Cheng, Chien-Yu, et al.
Publicado: (2020)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study
por: Wong, Carlos K. H., et al.
Publicado: (2022)

Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort
por: Karolyi, Mario, et al.
Publicado: (2020)

Lichen planus after SARS-CoV-2 infection treated with lopinavir/ritonavir()
por: Gimeno Castillo, Javier, et al.
Publicado: (2021)

Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19
por: Binois, Yannick, et al.
Publicado: (2020)

Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19
por: Echarte-Morales, Julio, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_03lmqk7vvpoli6g41dja17384b